Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 18, 2008. The report addresses the termination of Variable Sales Forward (VSF) Agreements with Lehman Brothers Finance S.A. regarding 20 million shares of Quest Diagnostics Inc. common stock.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial metric disclosed is the confirmation that the termination of the VSF Agreements is expected to have no material financial impact on GSK.
Material Changes
The primary material change reported is the termination of the VSF Agreements with Lehman Brothers Finance S.A. Consequently, GSK has requested the return of the 20 million pledged Quest Diagnostics Inc. shares held in custody by Lehman Brothers Inc.
Outlook, Risks, and Management Commentary
Management, represented by Company Secretary Simon Bicknell, confirmed the termination of the agreements. The filing explicitly states that no material financial impact is expected from this event. No other risks, contingencies, or forward-looking guidance are provided in this specific document.
Investor Verification Checklist
- Verify the status of the 20 million Quest Diagnostics Inc. shares pledged to Lehman Brothers Inc.
- Confirm that the termination of the VSF Agreements has resulted in no unexpected financial charges or gains.
- Monitor subsequent filings for any updates regarding the return of the pledged shares.